li001

RD118 CAR T Therapy Shows High Response Rates in Advanced Multiple Myeloma Phase 1 Trial

Clinical Trails /

A Phase 1 trial of RD118, a novel fully human anti-GPRC5D CAR T-cell therapy, showed strong and durable responses in heavily pretreated patients with relapsed or refractory multiple myeloma. The study enrolled 18 patients, many with high-risk disease, including prior BCMA CAR T failure. With a median follow-up of 17 months, the overall response rate […]

RD118 CAR T Therapy Shows High Response Rates in Advanced Multiple Myeloma Phase 1 Trial Read More »

TALAPRO-2 Analysis Supports rPFS as Surrogate for Survival in Metastatic Prostate Cancer

Treatment /

A new post hoc analysis of the phase 3 TALAPRO-2 trial found that radiographic progression-free survival (rPFS) strongly correlates with overall survival (OS) in first-line metastatic castration-resistant prostate cancer (mCRPC). The analysis evaluated patients treated with Talazoparib plus Enzalutamide or enzalutamide alone and showed consistent moderate-to-strong correlations across all major patient groups. The strongest association

TALAPRO-2 Analysis Supports rPFS as Surrogate for Survival in Metastatic Prostate Cancer Read More »

Immunotherapy Expands Into Earlier Treatment for High-Risk Cutaneous Squamous Cell Carcinoma

Immunotherapy /

Cutaneous squamous cell carcinoma (CSCC) is becoming increasingly defined by personalized treatment decisions based on whether tumors are surgically removable. Unlike basal cell carcinoma, which grows slowly and rarely spreads, CSCC is more aggressive and can invade nerves, lymph nodes, and distant organs, especially in immunosuppressed patients. For unresectable or metastatic disease, FDA-approved anti–PD-1 immunotherapies

Immunotherapy Expands Into Earlier Treatment for High-Risk Cutaneous Squamous Cell Carcinoma Read More »

EGFR Bispecific Therapies and Proton Radiation Advance Head and Neck Cancer Care

Technology Innovation /

Emerging therapies are reshaping treatment for head and neck cancer, particularly in recurrent or metastatic HPV-negative disease. EGFR-directed bispecific antibodies are showing promising activity and could enter standard care within the next few years. Amivantamab received FDA breakthrough therapy designation in 2026 for recurrent or metastatic HPV-unrelated head and neck squamous cell carcinoma after chemotherapy

EGFR Bispecific Therapies and Proton Radiation Advance Head and Neck Cancer Care Read More »

Study Identifies KRT19 as Key Driver of Gastric Cancer Metastasis

Research Advances /

A new study found that the protein KRT19 may play a major role in helping gastric cancer spread. Researchers discovered that KRT19 does more than provide structural support inside cells. Instead, it can move into the cell nucleus and activate signals that increase cancer cell movement and invasion. The study showed that KRT19 levels were

Study Identifies KRT19 as Key Driver of Gastric Cancer Metastasis Read More »

JNJ-1900 Shows Promising Early Results in Stage 3 Unresectable NSCLC

Clinical Trails /

Early results from the phase 2 CONVERGE trial show that JNJ-1900 can be safely combined with standard concurrent chemoradiotherapy for patients with stage 3 unresectable non–small cell lung cancer. JNJ-1900 is a nanoparticle-based radioenhancer injected directly into tumors or lymph nodes before radiation treatment. Investigators reported that the injection procedure was feasible and did not

JNJ-1900 Shows Promising Early Results in Stage 3 Unresectable NSCLC Read More »

New Framework Defines Best Use of Tissue NGS and Liquid Biopsy in Metastatic Colorectal Cancer

Diagnostics /

A new expert framework highlights how tissue next-generation sequencing (NGS) and liquid biopsy (ctDNA) should be used together in metastatic colorectal cancer rather than as interchangeable tests. Experts recommend ordering both at diagnosis because chemotherapy can quickly reduce ctDNA shedding, making later liquid biopsies less informative. Tissue testing captures the local tumor environment, while ctDNA

New Framework Defines Best Use of Tissue NGS and Liquid Biopsy in Metastatic Colorectal Cancer Read More »

Enhertu Recommended by EMA for HER2-Positive Solid Tumors Across Multiple Cancer Types

Drug Approvals /

The European Medicines Agency’s CHMP has recommended approval of Enhertu for adults with previously treated, unresectable, or metastatic HER2-positive (IHC 3+) solid tumors lacking satisfactory treatment options. If approved by the European Commission, it would become the first HER2-targeted tumor-agnostic antibody-drug conjugate available in the European Union. The recommendation is supported by phase 2 trials

Enhertu Recommended by EMA for HER2-Positive Solid Tumors Across Multiple Cancer Types Read More »

FDA-Approved Opdivo and Yervoy Combination Redefines First-Line Liver Cancer Treatment

Drug Approvals /

The FDA-approved combination of Opdivo plus Yervoy is rapidly reshaping first-line treatment for advanced hepatocellular carcinoma (HCC). The April 2025 approval was based on results from the phase 3 CheckMate 9DW trial, which compared the immunotherapy combination against standard tyrosine kinase inhibitors, including Lenvima and Nexavar. The study showed the immunotherapy regimen improved median overall

FDA-Approved Opdivo and Yervoy Combination Redefines First-Line Liver Cancer Treatment Read More »

Cats and Humans Share Key Cancer Genes in Landmark Global Study

Research Advances /

A major international study has created the first large-scale genetic map of cancer in domestic cats, offering new insights that may benefit both veterinary and human medicine. Researchers analyzed tumor samples from nearly 500 cats across five countries and discovered that feline cancers share many of the same cancer-driving genes seen in humans and dogs,

Cats and Humans Share Key Cancer Genes in Landmark Global Study Read More »